Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2017

Weiss Glen J, Beck Julia, Braun Donald P, Bornemann-Kolatzki Kristen, Barilla Heather, Cubello Rhiannon, Quan Walter, Sangal Ashish, Khemka Vivek, Waypa Jordan, Mitchell William M, Urnovitz Howard, Schütz Ekkehard

Abstract excerpt

Purpose: Chromosomal instability is a fundamental property of cancer, which can be quantified by next-generation sequencing (NGS) from plasma/serum-derived cell-free DNA (cfDNA). We hypothesized that cfDNA could be used as a real-time surrogate for imaging analysis of disease status as a function of response to immunotherapy and as a more reliable tool than tumor biomarkers.Experimental Design: Plasma cfDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Chromosomal Instability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Disease Progression

Share to DNA Copy Number Variations

Share to High-Throughput Nucleotide Sequencing

Share to Immunotherapy

Share to T-Lymphocytes, Regulatory

Source

Identifiers

PMID: 28320758
DOI: 10.1158/1078-0432.CCR-17-0231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.PMID 28320758Read ↗

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer PatientsSemantic proximity Read ↗

Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterationsSemantic proximity Read ↗

Using circulating cell-free DNA to monitor personalized cancer therapySemantic proximity Read ↗

Fraction of copy-number alterations significantly predicts survival following immunotherapy in a few cancersSemantic proximity Read ↗

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.Semantic proximity Read ↗

The average copy number variation (CNVA) of chromosome fragments is a potential surrogate marker for TMB in predicting responses to immunotherapy in Non-small cell lung cancerSemantic proximity Read ↗

Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell LymphomasSemantic proximity Read ↗

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.Semantic proximity Read ↗

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapySemantic proximity Read ↗

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with SorafenibSemantic proximity Read ↗

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal MassesSemantic proximity Read ↗

Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.